Dr. Albert O. Edwards, MD, PHD
Retina Specialist (Retina Specialist (Ophthalmology) Physician)
- Medicare participating
At a glance
- Medical school
- Baylor College of Medicine (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 486
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: Baylor College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Retina Specialist (Ophthalmology) Physician primary
OR license MD20042 -
Ophthalmology Physician
OR license MD20042 -
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician
OR license MD20042
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Sterling Vision PC (9 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 486
- Services billed
- 14,361
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 4,920 | 14 |
| Imaging of retina | 1,738 | 499 |
| Injection, aflibercept, 1 mg | 1,692 | 139 |
| Injection of drug into eye | 1,179 | 258 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 1,050 | 44 |
| Established patient office or other outpatient visit, 30-39 minutes | 904 | 412 |
| Injection, bevacizumab, 10 mg | 433 | 96 |
| Established patient office or other outpatient visit, 20-29 minutes | 396 | 216 |
| Injection, brolucizumab-dbll, 1 mg | 294 | 12 |
| Unclassified drugs | 198 | 38 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 10 payments worth $1,076 in total to this clinician.
| Bausch & Lomb Americas Inc. | $218 |
|---|---|
| Alcon Research LLC | $182 |
| Alcon Vision LLC | $147 |
| Tarsus Pharmaceuticals, Inc. | $130 |
| Sun Pharmaceutical Industries Inc. | $107 |
| Heidelberg Engineering, Inc. | $93.70 |
| Rxsight Inc | $86.53 |
| Regeneron Pharmaceuticals, Inc. | $84.60 |
| Food and Beverage | $1,076 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 17 industry-funded studies in 2025, from 9 companies. The companies reported $660,061 in research payments for these studies, mostly to the institutions running them.
- A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular dege…
Boehringer Ingelheim Pharmaceuticals, Inc. - JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862
Boehringer Ingelheim Pharmaceuticals, Inc. - An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
Apellis Pharmaceuticals, Inc. - Entry into human of RO7497372 in participants with diabetic macular edema
Roche Tcrc, Inc. - ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
Novartis Pharmaceuticals Corporation - A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
Sanofi US Services Inc. · Active, not recruiting · NCT06660667 - A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704 - A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy …
Janssen Research & Development, LLC - A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy …
Janssen Research & Development, LLC - A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Pati…
Apellis Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.